On Jul. 30, 2021, Regeneron announced that the FDA had updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COVﾙ (casirivimab and imdevimab).

The authorization now included post-exposure prophylaxis in people at high risk for progression to severe COVID-19, who were not fully vaccinated or were not expected to mount an adequate response to vaccination, and had been exposed to a SARS-CoV-2.